EAU 2018

EAU 2018: Low Dose Gemcitabine Increases the Cytotoxicity of Human γδT Cell in In Vitro and in an Orthotopic Xenograft Model in Bladder Cancer

Copenhagen, Denmark (UroToday.com) There has long been an effort to identify an effective salvage therapy for NMIBC patients who fail intravesical BCG. Unfortunately, at this time, radical cystectomy remains the best option for these patients. Many agents have been tested and failed to demonstrate significant benefit. However, many newer agents, including immunotherapy agents, are currently in clinical trial. The advantages of an effective BCG salvage are obvious – avoiding cystectomy is an important goal for many patients and physicians, due to the significant impact on patients QOL.

EAU 2018: Influence of Diabetes on the Risk of Urothelial Cancer According to Body Mass Index: A 10-Year Nationwide Population-Based Observational Study

Copenhagen, Denmark (UroToday.com) Obesity and diabetes, and their associated sequelae, have been associated with increase rates of malignancy and worse oncologic outcomes in many different settings. While not always a causal relationship, the association is important. 

EAU 2018: Prostate Cancer Bi-Parametric Versus Multi-Parametric Magnetic Resonance Imaging

Copenhagen, Denmark (UroToday.com) Dr. Barentsz presented an overview of the roles of different modalities encompassed within multiparametric MRI (mpMRI) prostate imaging. Three types of images are usually obtained when imaging the prostate, which help to grade lesions via the PIRADS system. T2 images are good at demonstrating anatomy. Diffusion-weighted images (DWI) are good for demonstrating biology within the tissues. Dynamic contrast enhanced images (DCE) show the vascularity within the tissues. 

EAU 2018: Patient-Reported Outcome Measures in Men with Non-Metastatic Castration-Resistant Prostate Cancer: Baseline Data from the PROSPER Trial

Copenhagen, Denmark (UroToday.com) At GU ASCO 2018, Dr. Maha Hussain presented the data from the PROSPER study, which was an incredibly important study looking at the role for enzalutamide (ENZA) in the setting of non-metastatic castration-resistant prostate cancer (nmCRPC). There was a 71% risk reduction of metastases; MFS was 36.6 months in the ENZA arm compared to just 14.7 months in the placebo arm.

EAU 2018: New Molecular Tumor Markers for Germ Cell Tumors - Ready for Prime Time?

Copenhagen, Denmark (UroToday.com) Testis cancer has been one of few cancers (Prostate (PSA), Colon Cancer (CEA), Ovarian Cancer (CA19-9)) where serum biomarkers play a significant role in staging and in the assessment of treatment response. Unfortunately, the current biomarkers (AFP, HCG, and LDH) are only elevated in ~ 50% of cases and tend to be of minimal value in patients presenting with low stage disease. To date, we are in dire need for tumor-specific biomarkers that allow for better risk stratify patients, especially those with stage I disease, where overtreatment is a significant concern. Dr. Deickmann, from Hamburg, presents data on a novel microRNA based biomarker that is showing remarkable promise to become a testis cancer-specific biomarker. 

EAU 2018: Simple Biparametric MRI in Detection and Ruling Out Significant Prostate Cancer in Biopsy-Naïve Men - BIDOC Study

Copenhagen, Denmark (UroToday.com) Dr. Boesen and colleagues presented results of simple biparametric MRI (bpMRI) for detecting prostate cancer in biopsy-naïve men. Standard transrectal ultrasound-guided biopsies in men with clinical suspicion of prostate cancer are prone to sampling errors due to difficulties in target identification. Multiparametric MRI (mpMRI) has been shown to improve detection and risk stratification of prostate cancer. However, mpMRI is time-consuming and costly. A simpler and rapid (~15 min) biparametric MRI (bpMRI) using fewer scan sequences and no intravenous contrast-media could provide a basis for a prostate MRI triage test before any biopsy in a large scale. The objective of this study was to prospectively assess the diagnostic accuracy and negative predictive value (NPV) of a novel bpMRI method in biopsy-naive men in detection and ruling out significant prostate cancer in confirmatory biopsies.

EAU 2018: The FUTURE Trial: A RCT on MRI Targeted Prostate Biopsy: Comparison of Targeted and Systematic Biopsy Outcomes

Copenhagen, Denmark (UroToday.com) Guidelines advise a multiparametric MRI (mpMRI) in patients with prior negative systematic biopsies and a persisting suspicion of prostate cancer prostate cancer, enabling targeted biopsy if tumor suspicious lesions are present. Dr. Exterkate presented results of the FUTURE trial, comparing targeted and systematic biopsy results. The objective of this analysis of the FUTURE trial was to assess detection rates of (significant) prostate cancer using targeted biopsy vs detection rates using systematic biopsy.